Successful Liver Transplantation From a SARS-CoV-2 Positive Donor to a Positive Recipient: Potential Role of Monoclonal Antibodies

Abstract

while remaining on the transplant waitlist. SARS-CoV-2-directed monoclonal antibody therapy and/or preemptive remdesivir administration may have roles in this setting; however, additional studies on strategies to mitigate donor-derived COVID-19 are necessary.

Utilization and outcomes of deceased donor SARS-CoV-2–positive organs for solid organ transplantation in the United States

“…These data complement prior smaller single‐center reports and case series and may provide assurance that, at least short‐term outcomes are not compromised by use of these organs. 7 , 8 , 9 , 10 , 11 , 13 , 20 , 21 In the context of kidney transplantation, the current study indicated no difference in rates of delayed graft function or 6‐month graft survival and the characteristics of recipients was similar between negative and positive SARS‐CoV‐2 status donors. Similarly for liver and transplant recipients, both general characteristics of recipients and 6‐month graft survival were similar by SARS‐CoV‐2 status donors.…”

“… 7 , 8 , 9 Due to ongoing uncertainties regarding the relative risks of transplantation with donors with prior or active infections, evidence for the safe use of organs from SARS‐CoV‐2–positive donors has emerged slowly with small case series from individual centers. 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 Although early results appear promising, best practices for utilization of positive SARS‐CoV‐2 donors remain unclear. 7 , 8 , 9 , 11 , 17 , 18 , 19 …”

“… 8 , 10 , 11 , 12 , 13 , 14 , 15 , 16 Although early results appear promising, best practices for utilization of positive SARS‐CoV‐2 donors remain unclear. 7 , 8 , 9 , 11 , 17 , 18 , 19 …”

“…[7][8][9] Due to ongoing uncertainties regarding the relative risks of transplantation with donors with prior or active infections, evidence for the safe use of organs from SARS-CoV-2-positive donors has emerged slowly with small case series from individual centers. 8,[10][11][12][13][14][15][16] Although early results appear promising, best practices for utilization of positive SARS-CoV-2 donors remain unclear. [7][8][9]11,[17][18][19] In the current study, our aims were to characterize processes of care and outcomes associated with SARS-CoV-2 donation and transplantation in the United States.…”

“…8,[10][11][12][13][14][15][16] Although early results appear promising, best practices for utilization of positive SARS-CoV-2 donors remain unclear. [7][8][9]11,[17][18][19] In the current study, our aims were to characterize processes of care and outcomes associated with SARS-CoV-2 donation and transplantation in the United States. We sought to evaluate the incidence and type of SARS-CoV-2 testing over time.…”